Current status of diagnosis and Mesenchymal stem cells therapy for acute pancreatitis

Abstract

Acute pancreatitis (AP) is an acute gastrointestinal disorder that is the most common and requiring emergency hospitalization. Its incidence is increasing worldwide, thus increasing the burden of medical services. Approximately 20% of the patients develop moderate to severe necrotizing pancreatitis associated with pancreatic or peri‐pancreatic tissue necrosis and multiple organ failure. There are many reports about the anti‐inflammatory effect of mesenchymal stem cells (MSCs) on pancreatitis and the repair of tissue damage. MSCs cells come from a wide range of sources, autologous MSCs come from bone marrow and allogeneic MSCs such as umbilical cord blood MSCs, placenta‐derived MSCs, etc. The wide source is not only an advantage of MSCs but also a disadvantage of MSCs. Because of different cell sources and different methods of collection and preparation, it is impossible to establish a unified standard method for evaluation of efficacy. The biggest advantage of iMSCs is that it can be prepared by a standardized process, and can be prepared on a large scale, which makes it easier to commercialize. This paper reviews the present status of diagnosis and progress of MSCs therapy for AP.

Rejuvenation of Helicobacter pylori–Associated Atrophic Gastritis Through Concerted Actions of Placenta-Derived Mesenchymal Stem Cells Prevented Gastric Cancer

“…PD-MSCs have multiple properties, including strong selfrenewal, multi-potent differentiation, immunomodulatory, anti-inflammatory, antioxidative, and regenerative capabilities (Kim M. J. et al, 2011;Seok et al, 2020a;Chou and Chen, 2020;Saleh et al, 2020;Yuan et al, 2020). Among the various types of MSCs, including umbilical cord-derived MSCs, chorionic plate-derived MSCs, adipose-derived MSCs, and bone marrow-derived MSCs, PD-MSCs are best known for their secretion of various cytokines, including growth factors such as G-CSF; regulated upon activation, normal T cell expressed and secreted (RANTES); and immunomodulators such as IL-6, IL-8, and IL-10, and have been linked to the effective treatment of various degenerative and destructive diseases (Lee et al, 2010;Lee et al, 2012;Jung et al, 2013;Munir et al, 2019;Seok et al, 2020b). The reasons why the MSCs have emerged among the most promising regenerative tools are closely linked to their multi-differentiation potential and immunosuppressive capacity.…”

A narrative review of acute pancreatitis and its diagnosis, pathogenetic mechanism, and management

“…However, exosomes derived from different cells may play different roles in the pathogenesis of AP. For example, exosomes derived from bone marrow mesenchymal stem cells (MSCs) have a healing effect on AP (86). In addition, exosomes-miR-223-3p from MSCs can also attenuate cerebral injury via inhibiting M1 polarization mediated pro-inflammatory response, which may be related with a negative effect on exosomes-miR-223-3p for CysLT 2 R (87).…”

Research Progress on Tissue Engineering of Main Tissues and Organs of Human Body

“…[20] Human amniotic mesenchymal stem cells can reduce immune responses in allograft models in vitro, indicating the potential value of such cells in the treatment of premature newborns and post-transplant treatment. [21] In addition, mesenchymal stem cells can be used to treat multiple sclerosis [22], Duchenne muscular dystrophy [23], tumor disease [24], and acute pancreatitis [25].…”